Pakistan's First and only MHRA CGMP Certified Company


 (An Effective Remedy for Breast Cancer)

Femizole® is a non-steroidal aromatase inhibitor and an antineoplastic agent. It is formulated for treating postmenopausal women with breast cancer.

Active Ingredients

Letrozole: Letrozole is an oral anti-estrogen drug used to inhibit estrogen biosynthesis.

Mechanism of Action

In postmenopausal women, aromatase is responsible for the production of estrogen. It converts androgen to estrogen. Breast tissue is stimulated by estrogen. Femizole® works by competitively binding to the aromatase enzyme, which results in the reduction of estrogen biosynthesis. Thus decreasing the estrogen – dependent tumors.


Femizole® is used:

  • To Treat invasive early hormone-receptor-positive breast cancer in postmenopausal women who have received tamoxifin therapy
  • As first-line treatment of hormone-dependent advanced cancer in postmenopausal women
  • For advanced breast cancer after relapse in postmenopausal women
  • As neo adjuvant hormone-receptor-positive breast cancer in postmenopausal women


Dosage & Instructions

Dosage and the length of the treatment should be prescribed by the doctor according to the patient’s condition.

However, the usual dose is 2.5 mg once, daily.

In adjuvant and extended adjuvant breast cancer:

Treatment should continue for 5 years until the disease relapses.

In neo adjuvant setting:

Treatment should continue for 4-8 months.